Effects of Escitalopram on Markers of Bone Turnover: A Randomized Clinical Trial
Open Access
- 1 September 2014
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 99 (9) , E1732-E1737
Abstract
Context: Recent observational studies have suggested that the use of selective serotonin reuptake inhibitors is associated with an increased fracture risk and an accelerated bone loss, although conflicting results have been reported. Furthermore, because many of these studies have been performed in depressed women, confounding by indication may influence these findings. Objective: The objective of the study was to determine whether selective serotonin reuptake inhibitors affect bone metabolism Design: This was a randomized controlled trial. Setting: The study was conducted in four US clinical sites. Participants: Healthy peri- and postmenopausal women participated in the study. Intervention: The intervention was escitalopram (10–20 mg/d) for the treatment of vasomotor symptoms. Main Outcome Measures: Serum carboxyterminal collagen crosslinks (CTX) and serum amino-terminal propeptide of type I collagen (P1NP) were measured. Results: One hundred forty-one peri- or postmenopausal nondepressed women (mean age 53.7 y, SD 4.1) had baseline and 8-week follow-up samples available for analysis and were included in the study (69 escitalopram, 72 placebo). The groups were balanced across a broad range of baseline characteristics, including age, race, body mass index, smoking status, and mood symptoms. The between-group differences in the change in CTX and P1NP from baseline to week 8 were compared by a repeated-measures linear regression model adjusted for race, clinical center, and baseline measurement. Treatment with escitalopram reduced serum P1NP by 1.02 ng/mL on average [95% confidence interval (CI) −5.17, 3.12] compared with a reduction of 1.88 ng/mL (95% CI −4.82, 1.06) in the placebo group (P = .65). Similarly, serum CTX decreased 0.02 ng/mL on average (95% CI −0.05, 0.01) in the escitalopram group compared with 0.00 ng/mL (95% CI −0.02, 0.02) in the placebo group (P = .24). The results were similar when the analysis was restricted to those women whose adherence to study medication was 70% or greater. Conclusions: Although the study was limited to 8 weeks, these results suggest that escitalopram does not significantly alter bone metabolism in the short term.Keywords
This publication has 19 references indexed in Scilit:
- Rates of Bone Loss Among Women Initiating Antidepressant Medication Use in MidlifeThe Journal of Clinical Endocrinology & Metabolism, 2013
- Serotonin–norepinephrine reuptake inhibitor therapy in late-life depression is associated with increased marker of bone resorptionOsteoporosis International, 2013
- Treatment of a major depression episode suppresses markers of bone turnover in premenopausal womenJournal of Psychiatric Research, 2011
- Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case–control studiesOsteoporosis International, 2011
- Effects of selective serotonin reuptake inhibitors on bone health in adults: Time for recommendations about screening, prevention and management?Bone, 2010
- The emerging role of serotonin (5-hydroxytryptamine) in the skeleton and its mediation of the skeletal effects of low-density lipoprotein receptor-related protein 5 (LRP5)Bone, 2010
- SSRIs, bone mineral density, and risk of fractures — a reviewEuropean Neuropsychopharmacology, 2009
- Faculty Opinions recommendation of Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from clinical studies.2009
- Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal WomenThe Journal of Clinical Endocrinology & Metabolism, 2008
- The PHQ-9Journal of General Internal Medicine, 2001